Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Myelofibrosis"" wg kryterium: Temat


Starter badań:

Tytuł:
Impact of CALR and JAK2 V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.
Autorzy:
Narlı Özdemir Z; İzmir City Hospital, Clinic of Hematology, İzmir, Türkiye.
İpek Y; Kartal Dr. Lüfti Kırdar City Hospital, Clinic of Hematology, İstanbul, Türkiye.
Patır P; Antalya Training and Research Hospital, Clinic of Hematology, Antalya, Türkiye.
Ermiş G; Karadeniz Technical University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Trabzon, Türkiye.
Çiftçiler R; Selçuk University Faculty of Medicine, Department of Hematology, Konya, Türkiye.
Özmen D; İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye.
Baysal M; Ali Osman Sönmez Oncology Hospital, Clinic of Hematology, Bursa, Türkiye.
Gürsoy V; Bursa City Hospital, Clinic of Orthopedics and Traumatology, Bursa, Türkiye.
Yıldızhan E; Kayseri City Hospital, Clinic of Hematology, Kayseri, Türkiye.
Güven S; Mehmet Akif Ersoy State Hospital, Clinic of Hematology, Çanakkale, Türkiye.
Ercan T; Haydarpaşa Numune Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye.
Elibol T; Medeniyet University Göztepe Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye.
Mersin S; Muğla Sıtkı Koçman University Training and Research Hospital, Clinic of Hematology, Muğla, Türkiye.
Genç E; Tekirdağ Dr. İsmail Fehmi Cumalıoğlu City Hospital, Clinic of Hematology, Tekirdağ, Türkiye.
Davulcu EA; University of Health Sciences Türkiye, İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye.
Karakuş V; Antalya Training and Research Hospital, Clinic of Hematology, Antalya, Türkiye.
Erkut N; Karadeniz Technical University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Trabzon, Türkiye.
Güneş G; University of Health Sciences Türkiye, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Clinic of Hematology, Ankara, Türkiye.
Diz Küçükkaya R; İstanbul University Faculty of Science, Department of Molecular Biology and Genetics, İstanbul, Türkiye.
Eşkazan AE; İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye.
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Mar 01; Vol. 41 (1), pp. 26-36.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Primary Myelofibrosis*
Thrombocythemia, Essential*/drug therapy
Thrombocythemia, Essential*/genetics
Thrombosis*/etiology
Thrombosis*/genetics
Humans ; Calreticulin/genetics ; Disease Progression ; Hemoglobins ; Mutation ; Retrospective Studies ; Turkey/epidemiology
Czasopismo naukowe
Tytuł:
Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.
Autorzy:
Mahmud M; Department of Medicine, Midwestern University Internal Medicine Residency Consortium, Cottonwood, AZ 86326, USA.
Vasireddy S; Department of Medicine, University of Arizona Health Sciences, Tucson, AZ 85701, USA.
Gowin K; Division of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ 85701, USA.
Amaraneni A; Division of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ 85701, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 12; Vol. 24 (24). Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Myeloproliferative Disorders*/diagnosis
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/therapy
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/genetics
Primary Myelofibrosis*/therapy
Neoplasms*
Humans ; Chromosome Aberrations ; Mutation
Czasopismo naukowe
Tytuł:
Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.
Autorzy:
Beleva EA; Clinic of Hematology, Military Medical Academy, 1606 Sofia, Bulgaria.; QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 29; Vol. 24 (21). Date of Electronic Publication: 2023 Oct 29.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Primary Myelofibrosis*/complications
Primary Myelofibrosis*/genetics
Myeloproliferative Disorders*/genetics
Venous Thrombosis*/genetics
Polycythemia Vera*
Thrombosis*/genetics
Thrombosis*/complications
Thrombocythemia, Essential*
Humans ; Phenotype
Czasopismo naukowe
Tytuł:
Fibrosis and bone marrow: understanding causation and pathobiology.
Autorzy:
Ghosh K; National Institute of Immunohaematology, 13 Th Fl KEM Hospital, Parel, Mumbai, 400012, India. .
Shome DK; Department of Pathophysiology, American University of Antigua College of Medicine, Coolidge, Antigua and Barbuda.
Kulkarni B; Department of Molecular Biology and Haemostasis, National Institute of Immunohaematology, 13Th Fl KEM Hospital, Parel, Mumbai, 400012, India.
Ghosh MK; Department of Haematology, Nilratan Sarkar Medical College, Kolkata, 700014, West Bengal, India.
Ghosh K; Department of Clinical Biochemistry, Tata Medical Centre and Homi Bhaba National Institute, Parel, Mumbai, 400012, India.
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Oct 09; Vol. 21 (1), pp. 703. Date of Electronic Publication: 2023 Oct 09.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Bone Marrow*/metabolism
Primary Myelofibrosis*/etiology
Primary Myelofibrosis*/metabolism
Primary Myelofibrosis*/pathology
Humans ; Cytokines/metabolism ; Fibrosis ; Chemokines/metabolism ; Hormones
Czasopismo naukowe
Tytuł:
Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients.
Autorzy:
Cherdchoo N; Faculty of Medicine Chulalongkorn University, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Polprasert C; Faculty of Medicine Chulalongkorn University, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.; Faculty of Medicine, Center of excellence in Translational Hematology, Division of Hematology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand.
Rojnuckarin P; Faculty of Medicine Chulalongkorn University, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.; Faculty of Medicine, Center of excellence in Translational Hematology, Division of Hematology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand.
Kongkiatkamon S; Faculty of Medicine Chulalongkorn University, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.; Faculty of Medicine, Center of excellence in Translational Hematology, Division of Hematology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2280731. Date of Electronic Publication: 2023 Nov 09.
Typ publikacji:
Journal Article
MeSH Terms:
Myeloproliferative Disorders*/complications
Primary Myelofibrosis*/complications
Leukemia*
Humans ; Quality of Life ; Southeast Asian People
Czasopismo naukowe
Tytuł:
Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study.
Autorzy:
Svingel LS; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Denmark.
Christensen SF; Department of Hematology, Zealand University Hospital, Denmark.
Kjærsgaard A; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Denmark.
Stenling A; Novartis Sverige AB, Sweden.
Paulsson B; Novartis Sverige AB, Sweden.
Andersen CL; Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Denmark.
Christiansen CF; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Denmark.
Stentoft J; Department of Hematology, Aarhus University Hospital, Denmark.
Starklint J; Department of Medicine, Goedstrup Hospital, Denmark.
Severinsen MT; Department of Hematology, Aalborg University Hospital, Denmark.
Borg Clausen M; Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Denmark.
Hagemann Hilsøe M; Department of Hematology, Hospital of South West Jutland, Denmark.
Hasselbalch HC; Department of Hematology, Zealand University Hospital, Denmark.
Frederiksen H; Department of Hematology, Odense University Hospital, Denmark.
Bak M; Department of Hematology, Zealand University Hospital, Denmark.
Mikkelsen EM; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Denmark.
Pokaż więcej
Źródło:
Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2023 Oct; Vol. 62 (10), pp. 1286-1294. Date of Electronic Publication: 2023 Sep 01.
Typ publikacji:
Journal Article
MeSH Terms:
Polycythemia Vera*/epidemiology
Primary Myelofibrosis*/epidemiology
Thrombocythemia, Essential*
Myeloproliferative Disorders*
Humans ; Cohort Studies
Czasopismo naukowe
Tytuł:
Autoinflammation and Myelofibrosis: Report of a Case
Autorzy:
Koduri PR; Mahavir Hospital and Research Centre, Department of Medicine, Hyderabad, India
Shaik A; Apollo Hospital, Division of Hematology Laboratory, Hyderabad, India
Vegulada DR; Genes N Life Healthcare, Department of Molecular Diagnostics, Hyderabad, India
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2023 Aug 31; Vol. 40 (3), pp. 223-224. Date of Electronic Publication: 2023 Jul 31.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Primary Myelofibrosis*/diagnosis
Still's Disease, Adult-Onset*
Humans
Czasopismo naukowe
Tytuł:
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
Autorzy:
Verstovsek S; Leukemia Department, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. .
Mesa RA; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Medical Center Blvd, 11th Floor, Winston-Salem, NC, 27157, USA.
Livingston RA; Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE, 19803, USA.
Hu W; Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE, 19803, USA.
Mascarenhas J; Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY, 10029, USA.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2023 Jul 27; Vol. 16 (1), pp. 82. Date of Electronic Publication: 2023 Jul 27.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Primary Myelofibrosis*/drug therapy
Humans ; Quality of Life ; Janus Kinase 2 ; Nitriles/therapeutic use ; Pyrimidines/therapeutic use
Czasopismo naukowe
Tytuł:
Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
Autorzy:
Yönal-Hindilerden İ; İstanbul University İstanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye
Şahin E; İstanbul University İstanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye
Hindilerden F; University of Health Sciences Türkiye Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye
Dağlar-Aday A; İstanbul University İstanbul Medical Faculty, Department of Internal Medicine, Division of Medical Genetics, İstanbul, Türkiye
Nalçacı M; İstanbul University İstanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2023 Aug 31; Vol. 40 (3), pp. 174-182. Date of Electronic Publication: 2023 Aug 16.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/genetics
Myeloproliferative Disorders*/diagnosis
Myeloproliferative Disorders*/genetics
Polycythemia Vera*/genetics
Thrombocythemia, Essential*/diagnosis
Thrombocythemia, Essential*/genetics
Humans ; Alleles ; Splenomegaly ; Janus Kinase 2/genetics ; Mutation
Czasopismo naukowe
Tytuł:
Systemic inflammatory indices for predicting prognosis of myelofibrosis.
Autorzy:
Ersal T; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey. .
Özkocaman V; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Pınar İE; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Yalçın C; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Orhan B; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Candar Ö; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Çubukçu S; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Koca TG; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Hunutlu FÇ; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Yavuz Ş; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Ali R; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Özkalemkaş F; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059, Bursa, Turkey.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Aug 02; Vol. 13 (1), pp. 12539. Date of Electronic Publication: 2023 Aug 02.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/diagnosis
Humans ; Retrospective Studies ; Prognosis ; Inflammation/pathology ; Ferritins
Czasopismo naukowe
Tytuł:
Hemorrhagic Vesiculobullous Lesions of Ecthyma Gangrenosum in a Diabetic Patient with Myelofibrosis: A Rare Presentation of Septic Shock without Pseudomonas aeruginosa Bacteremia.
Autorzy:
Al Muqarrab FJ; Department of Dermatology, King Khalid Hospital, King Saud University Medical City, Riyadh, Saudi Arabia.
Al Mosbeh MJ; Intensive Care Unit, Prince Mohammed bin Abdulaziz Hospital, Riyadh, Saudi Arabia.
Al Haddad TA; Department of Internal Medicine, Adult Infectious Diseases, King Fahd Hospital, Hofuf, Saudi Arabia.
Al Muhainy NA; Department of Dermatology, King Fahd Hospital, Hofuf, Saudi Arabia.
Pokaż więcej
Źródło:
The American journal of case reports [Am J Case Rep] 2023 Jul 31; Vol. 24, pp. e939905. Date of Electronic Publication: 2023 Jul 31.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Ecthyma*/diagnosis
Ecthyma*/microbiology
Shock, Septic*/complications
Pseudomonas Infections*/complications
Pseudomonas Infections*/diagnosis
Pseudomonas Infections*/drug therapy
Primary Myelofibrosis*
Bacteremia*/complications
Bacteremia*/diagnosis
Diabetes Mellitus*
Male ; Humans ; Middle Aged ; Pseudomonas aeruginosa
Czasopismo naukowe
Tytuł:
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Autorzy:
Mesa RA; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
Hudgens S; Clinical Outcomes Solutions, Tucson, Arizona, USA.
Floden L; Clinical Outcomes Solutions, Tucson, Arizona, USA.
Harrison CN; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Palmer J; Mayo Clinic, Phoenix, Arizona, USA.
Gupta V; University Health Network, University of Toronto, Toronto, Ontario, Canada.
McLornan DP; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
McMullin MF; Queens University, Belfast City Hospital Trust, Belfast, UK.
Kiladjian JJ; Hôpital Saint-Louis, Université de Paris, Paris, France.
Foltz L; St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Platzbecker U; Leipzig University Hospital, Leipzig, Germany.
Fox ML; Hematology Department, Hospital Universitario Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitario Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Mead AJ; MRC Weatherall Institute of Molecular Medicine, Oxford, UK.
Ross DM; Flinders Medical Centre and University, Adelaide, South Australia, Australia.
Oh ST; Washington University School of Medicine, St. Louis, Missouri, USA.
Perkins A; Alfred Hospital, Monash University, Melbourne, Victoria, Australia.
Leahy MF; University of Western Australia, Perth, Western Australia, Australia.
Deheshi S; Sierra Oncology, Plymouth, Michigan, USA.
Donahue R; Sierra Oncology, Plymouth, Michigan, USA.
Klencke BJ; Sierra Oncology, Plymouth, Michigan, USA.
Verstovsek S; MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 May; Vol. 12 (9), pp. 10612-10624. Date of Electronic Publication: 2023 Apr 06.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Janus Kinase Inhibitors*/therapeutic use
Primary Myelofibrosis*/drug therapy
Primary Myelofibrosis*/diagnosis
Humans ; Benzamides ; Protein Kinase Inhibitors/therapeutic use ; Quality of Life
Czasopismo naukowe
Tytuł:
Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients.
Autorzy:
Pearson S; Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Blance R; Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Yan F; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
Hsieh YC; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
Geary B; Stoller Biomarker Discovery Centre, University of Manchester, Manchester, United Kingdom.
Amaral FMR; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
Somervaille TCP; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
Kirschner K; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
Whetton AD; Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Pierce A; Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 May 30; Vol. 18 (5), pp. e0286412. Date of Electronic Publication: 2023 May 30 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Primary Myelofibrosis*/drug therapy
Primary Myelofibrosis*/genetics
Myeloproliferative Disorders*/drug therapy
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/metabolism
Humans ; Mice ; Animals ; Proteomics ; Quality of Life ; Janus Kinase 2/metabolism ; Chromatin ; Mutation
Czasopismo naukowe
Tytuł:
Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference.
Autorzy:
Wang A; Pennsylvania State University, University Park, PA, 16802, USA.
Liu J; Hopkins School, 986 Forest Road, New Haven, CT, 06515, USA.
Pu JJ; Boston VA Medical Center/Brigham and Woman Hospital, Harvard Medical School, 1400 VFW Parkway Building 3, Suite 2B-115, Boston, MA, 02132, USA. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2023 May 12; Vol. 16 (1), pp. 53. Date of Electronic Publication: 2023 May 12.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Primary Myelofibrosis*/drug therapy
Primary Myelofibrosis*/genetics
Neoplasms*
Humans ; Janus Kinase 2/genetics ; Signal Transduction ; Mutation
Raport
Tytuł:
Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center
Autorzy:
Cengiz Seval G; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Civriz Bozdag S; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Toprak SK; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Kurt Yuksel M; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Topcuoglu P; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Arslan O; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Demirer T; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Gurman G; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Beksac M; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Ilhan O; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Ozcan M; Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
Pokaż więcej
Źródło:
Balkan medical journal [Balkan Med J] 2023 May 08; Vol. 40 (3), pp. 197-204. Date of Electronic Publication: 2023 Mar 24.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/surgery
Primary Myelofibrosis*/diagnosis
Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/etiology
Humans ; Treatment Outcome ; Retrospective Studies ; Cross-Sectional Studies
Czasopismo naukowe
Tytuł:
Porphyria Cutanea Tarda in a Patient with Myelofibrosis.
Autorzy:
Serrano-Ordóñez A; Department of Dermatology, Hospital Regional Universitario de Málaga, Málaga, Spain.
Godoy-Díaz DJ; Department of Dermatology, Hospital Regional Universitario de Málaga, Málaga, Spain.
Lova-Navarro M; Department of Dermatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Pokaż więcej
Źródło:
Sultan Qaboos University medical journal [Sultan Qaboos Univ Med J] 2023 May; Vol. 23 (2), pp. 274-275. Date of Electronic Publication: 2023 May 31.
Typ publikacji:
Journal Article
MeSH Terms:
Porphyria Cutanea Tarda*/complications
Porphyria Cutanea Tarda*/diagnosis
Primary Myelofibrosis*/complications
Primary Myelofibrosis*/diagnosis
Humans ; Risk Factors
Czasopismo naukowe
Tytuł:
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project.
Autorzy:
Coltro G; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Sant'Antonio E; GENOMEC Doctorate School, Medical Genetics, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Palumbo GA; Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate 'G.F. Ingrassia', University of Catania, Catania, Italy.
Mannelli F; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
De Stefano V; Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Rome, Italy.; Dipartimento DIRE, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
Ruggeri M; Hematology Department, San Bortolo Hospital, Vicenza, Italy.
Elli EM; Hematology Division and Bone Marrow Transplantation Unit, San Gerardo Hospital, ASST Monza, Monza, Italy.
Zanotti R; Section of Hematology, Department of Medicine, University Hospital of Verona, Verona, Italy.
Borsani O; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Bertozzi I; First Medical Clinic, Department of Medicine-DIMED, University of Padua, Padua, Italy.
Duminuco A; Postgraduate School of Hematology, University of Catania, Catania, Italy.
Betti S; Dipartimento DIRE, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
Carli G; Hematology Department, San Bortolo Hospital, Vicenza, Italy.
Cavalca F; Hematology Division and Bone Marrow Transplantation Unit, San Gerardo Hospital, ASST Monza, Monza, Italy.
Tanasi I; Section of Hematology, Department of Medicine, University Hospital of Verona, Verona, Italy.
Rumi E; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Randi ML; First Medical Clinic, Department of Medicine-DIMED, University of Padua, Padua, Italy.
Garibaldi B; Postgraduate School of Hematology, University of Catania, Catania, Italy.
Loscocco GG; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Guglielmelli P; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Vannucchi AM; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (7), pp. 8166-8171. Date of Electronic Publication: 2023 Jan 27.
Typ publikacji:
Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Primary Myelofibrosis*/complications
Humans ; Nitriles/therapeutic use ; Pyrimidines/therapeutic use ; Italy ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis.
Autorzy:
Lucijanic M; Hematology Department, University Hospital Dubrava, Zagreb, Croatia.; University of Zagreb School of Medicine, Zagreb, Croatia.
Krecak I; Department of Internal Medicine, General Hospital Sibenik, Sibenik, Croatia.; University of Rijeka School of Medicine, Rijeka, Croatia.
Soric E; Hematology Department, University Hospital Dubrava, Zagreb, Croatia.
Sabljic A; Hematology Department, University Hospital Dubrava, Zagreb, Croatia.
Galusic D; Department of Hematology, University Hospital Center Split, Split, Croatia.; University of Split School of Medicine, Split, Croatia.
Holik H; Department of Internal Medicine, 'Dr. Josip Bencevic' General Hospital, Slavonski Brod, Croatia.; University of Osijek Faculty of Medicine, Osijek, Croatia.
Perisa V; University of Osijek Faculty of Medicine, Osijek, Croatia.; Department of Hematology, Osijek University Hospital, Osijek, Croatia.
Peric MM; Department of Internal Medicine, General Hospital Zadar, Zadar, Croatia.
Zekanovic I; Department of Internal Medicine, General Hospital Zadar, Zadar, Croatia.
Kusec R; Hematology Department, University Hospital Dubrava, Zagreb, Croatia.; University of Zagreb School of Medicine, Zagreb, Croatia.
Pokaż więcej
Źródło:
Biochemia medica [Biochem Med (Zagreb)] 2023 Jun 15; Vol. 33 (2), pp. 020901. Date of Electronic Publication: 2023 Apr 15.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/genetics
Thrombosis*
Polycythemia Vera*
Humans ; Retrospective Studies ; Plasma Volume ; Prognosis ; Inflammation
Czasopismo naukowe
Tytuł:
JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Autorzy:
Stein BL; Division of Hematology/Oncology and Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 292-299. Date of Electronic Publication: 2022 Oct 27.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/drug therapy
Humans ; Protein Kinase Inhibitors/adverse effects ; Janus Kinase 2/genetics ; Pyrazoles/adverse effects ; Nitriles/therapeutic use
Czasopismo naukowe
Tytuł:
Trends in overall mortality among US veterans with primary myelofibrosis.
Autorzy:
Tashi T; Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah & SLC VAMC, Salt Lake City, UT, 84112, USA. .
Yu J; Incyte Corporation, Wilmington, DE, USA.
Pandya S; STATinMED LLC, Dallas, TX, USA.
Dieyi C; STATinMED LLC, Dallas, TX, USA.; Baylor College of Medicine, Houston, TX, USA.
Scherber R; Incyte Corporation, Wilmington, DE, USA.; UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA.
Parasuraman S; Incyte Corporation, Wilmington, DE, USA.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Jan 14; Vol. 23 (1), pp. 48. Date of Electronic Publication: 2023 Jan 14.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/drug therapy
Primary Myelofibrosis*/mortality
Veterans*
Adult ; Humans ; Nitriles ; Pyrazoles/pharmacology ; Retrospective Studies ; United States
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies